|

TAS-102 Clinical Trials

4 actively recruiting trials across 3 locations

Also known as: LONSURF, Lonsurf, tipiracil, trifluoridine and tipiracil, trifluridine

Pipeline

Phase 1: 2Phase 2: 1Phase 3: 1

Top Sponsors

  • University of California, Irvine1
  • Taiho Pharmaceutical Co., Ltd.1
  • M.D. Anderson Cancer Center1
  • AstraZeneca1

Indications

  • Cancer4
  • Colorectal Cancer3
  • Gastric Cancer2
  • Alveolar Soft Part Sarcoma1
  • Advanced or Metastatic Solid Tumor1

Other1 trial

AB122 Platform Study
Phase 1

Birmingham, Alabama1 trial

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3

Orange, California1 trial

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Chao Family Comprehensive Cancer Center, University of California, Irvine

Phase 1

Houston, Texas1 trial

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.